Table 5. Covariate analysis of minimal mean hepatic tolerance dose 6 weeks after BT (per protocol, n = 22).

Covariate*	p-value(group influence)	p-value(co-variate influence)
Sex (m/f)	0.015	0.458
Age (y)	0.016	0.864
Weight (kg)	0.010	0.117
Height (cm)	0.011	0.485
ECOG at baseline (0 and 1 vs 2)	0.008	0.310
EQ5D visual analogue score	0.015	0.868
History of liver surgery	0.007	0.064
Steatosis hepatis	0.014	0.845
Diabetes mellitus	0.015	0.627
Chemotherapy pre treatment	0.012	0.373
Used chemotherapeutic agents
Oxaliplatin	0.013	0.991
Irinotecan	0.011	0.327
Biologicals	0.012	0.459
Number of treated metastases	0.013	0.681
Maximum diamter of metastases (mm)	0.023	0.669
Clinical target volume (cm3)	0.013	0.815
Liver volume (cm3)	0.018	0.937
Interval from BT to 6 weeks FU (days)	0.008	0.258
Liver volume with a dose exposure >10 Gy (%)	0.013	0.598
Chemotherapy during follow-up	0.015	0.191
Bilirubin baseline	0.030	0.401
Albumin baseline	0.020	0.784
Aspartate transaminase baseline	0.025	0.263
Alanine transaminase baseline	0.006	0.092
Cholinesterase baseline	0.013	0.425
Gamma glutamyltransferase baseline	0.012	0.317
Glutamate dehydrogenase baseline	0.011	0.352
International normalized ratio baseline	0.008	0.783
Interleukin 6 baseline	0.030	0.401
Fibrinogen baseline	0.002	0.232
Factor VIII activity baseline	0.005	0.615
Protein C activity baseline	0.004	0.868
Protein S activity baseline	0.004	0.831
von Willebrand factor activity baseline	0.004	0.763
Antithrombin III activity baseline	0.008	0.261

*Two-way ANOVA for categorical factors, ANCOVA for metric covariables.